Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
March 10, 2008
- Takashi Kodama Elected JPA President
March 10, 2008
- Kitasato Univ.-Harvard School of Public Health Symposium
March 10, 2008
- Ethical Drugs Market Exceeds \8 Trillion in 2007: IMS
March 10, 2008
- Kyowa Hakko Licenses Antibody for Cancer Treatment
March 10, 2008
- Nucleic Acid-Based Drugs Will Be Innovative Drugs of Next Generation: Prof. Morishita
March 10, 2008
- Pfizer Japan Mobilizes All Employees, Officers to Defend Market for Norvasc
March 10, 2008
- GCP for Medical Devices to Be Amended
March 10, 2008
- TOPICS／Dr Karasawa Will Soon Be Back to Office: JMA
March 10, 2008
- Teijin's Gout Treatment TMX-67 Receives Approvable Letter in the EU
March 10, 2008
- Nippon Shinyaku Enters the Field of OB-GYN with IKH-01
March 10, 2008
- Kyowa Hakko Receives Not-Approvable Letter from FDA for Istradefylline
March 10, 2008
- Alfresa Directly Enters Kyushu Market
March 10, 2008
- Toledomin's Initial Dose to Be Changed Following Reexamination
March 10, 2008
- Schering-Plough Expands Its Pipeline by Acquisition of Organon
March 10, 2008
- Moves to Use iPS Cells for Drug Discovery Precipitated
March 10, 2008
- NEW PRODUCTS／Imigran Self-injection Kit for Headaches: GSK
March 10, 2008
- R&D NEWS IN BRIEF
March 10, 2008
- HUMIRA, Irbesartan Recommended for Approval
March 10, 2008
- NEW PRODUCTS／Shionogi: Allerport TARC
March 10, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…